
The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

Dr. Weidinger discusses the intricate neuroinflammatory mechanisms of chronic pruritic skin disease such as AD and PN.

ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.

Join Dr. Brian Kim in discussing the diagnosis of CPUO and the role of type 2 inflammation in disease pathophysiology.
Explore the clinical features, complex burden, and underlying mechanisms of PN.

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.
How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.
At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.

Learn about the pathophysiology of COPD and the involvement of chronic inflammation on the airways
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.